Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common clot drug fade stubborn skin darkening?

NCT ID NCT04233749

Symptom relief Sponsor: Henry Ford Health System Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This small phase 2 trial is testing whether tranexamic acid, a drug used to reduce bleeding, can lighten dark patches on the skin caused by lichen planus pigmentosus and erythema dyschromicum perstans. Five adults will take the drug twice daily for six months. Researchers will measure changes in pigmentation using special light devices.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tranexamic acid tablets
What this could lead to
If it works, this could offer a new treatment option for stubborn skin darkening conditions that currently have no effective therapy.
What could go wrong
This is a very small early-phase trial with only 5 participants, so results may not apply widely. Tranexamic acid also carries a risk of blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 5 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2020

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject age 18 and older * Subject with a diagnosis of LPP, EDP, or AD * Subject able to understand requirements of the study and risks involved * Subject able to sign a consent form * Subject to have discontinued all topical or oral medications, with the exception of sunscreen, used to treat pigmentary abnormalities one month prior to treatment Exclusion Criteria: * Personal history of clotting disorder or thromboembolic disease (deep vein thrombosis (DVT), stroke, etc) * Active malignancy, excluding non-melanoma skin cancer * Moderate to severe renal impairment * History of migraine with aura * Current anticoagulant therapy * Current use of hormonal contraception or hormone replacement therapy in the last 30 days * A woman who is lactating, pregnant, or planning to become pregnant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ashy dermatosis of ramirez are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lichen planus pigmentosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ashy dermatosis of ramirez Erythema dyschromicum perstans Lichen planus pigmentosus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • New Center One

    RECRUITING

    Detroit, Michigan, 48202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.